Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Joint pain and no interference with activity; Moderate muscle pain with some interference with activity; Moderate fever (101.3 to 102 °F); Headache and no interference with activity; Moderate fatigue with some interference with activity; Mild injection site redness; Moderate injection site swelling; Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement); This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)) and HEADACHE (Headache and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)), HEADACHE (Headache and no interference with activity), FATIGUE (Moderate fatigue with some interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)), HEADACHE (Headache and no interference with activity), FATIGUE (Moderate fatigue with some interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: 101.3 to 102 °F, Moderate fever..     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not provided.  Anytime during the 2 days after COVID-19 vaccination that is 24-Dec-2023 and 25-Dec-2023, patient experienced the events.  Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:same reporter